122 related articles for article (PubMed ID: 16454559)
21. A one-step prescreening for point mutations and large rearrangement in BRCA1 and BRCA2 genes using quantitative polymerase chain reaction and high-resolution melting curve analysis.
Coulet F; Pires F; Rouleau E; Lefol C; Martin S; Colas C; Cohen-Haguenauer O; Giurgea I; Fajac A; Noguès C; Demange L; Hardouin A; Lidereau R; Soubrier F
Genet Test Mol Biomarkers; 2010 Oct; 14(5):677-90. PubMed ID: 20858050
[TBL] [Abstract][Full Text] [Related]
22. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
Ganguly A; Leahy K; Marshall AM; Dhulipala R; Godmilow L; Ganguly T
Genet Test; 1997; 1(2):85-90. PubMed ID: 10464631
[TBL] [Abstract][Full Text] [Related]
23. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
24. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
25. Identification of BRCA1 and BRCA2 carriers by allele-specific gene expression (AGE) analysis.
Montagna M; Agata S; De Nicolo A; Menin C; Sordi G; Chieco-Bianchi L; D'Andrea E
Int J Cancer; 2002 Apr; 98(5):732-6. PubMed ID: 11920643
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK; Salo-Mullen E; Patil SM; Pietanza MC; Vijai J; Saloustros E; Hansen NA; Kauff ND; Kurtz RC; Kelsen DP; Offit K; Robson ME
Cancer; 2012 Jan; 118(2):493-9. PubMed ID: 21598239
[TBL] [Abstract][Full Text] [Related]
27. Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers.
Jiménez Ide J; Esteban Cardeñosa E; Palanca Suela S; González EB; Bolufer Gilabert P;
Clin Biochem; 2009 Oct; 42(15):1572-6. PubMed ID: 19616529
[TBL] [Abstract][Full Text] [Related]
28. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer.
Lu KH; Cramer DW; Muto MG; Li EY; Niloff J; Mok SC
Obstet Gynecol; 1999 Jan; 93(1):34-7. PubMed ID: 9916952
[TBL] [Abstract][Full Text] [Related]
29. High-resolution melting analysis for rapid screening of BRCA1 and BRCA2 Spanish mutations.
de Juan I; Esteban E; Palanca S; Barragán E; Bolufer P
Breast Cancer Res Treat; 2009 May; 115(2):405-14. PubMed ID: 18528753
[TBL] [Abstract][Full Text] [Related]
30. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
31. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.
Karp SE; Tonin PN; Bégin LR; Martinez JJ; Zhang JC; Pollak MN; Foulkes WD
Cancer; 1997 Aug; 80(3):435-41. PubMed ID: 9241077
[TBL] [Abstract][Full Text] [Related]
32. [Search for frequently encountered mutations in genes predisposing to breast cancer].
Mandel'shtam MIu; Golubkov VI; Lamber EP; Shapiro IM; Brezhneva TV; Semiglazov VF; Lipovetskiĭ BM; Hanson KP; Gaĭtskhoki VS
Genetika; 2001 Dec; 37(12):1681-6. PubMed ID: 11785296
[TBL] [Abstract][Full Text] [Related]
33. Convenient, nonradioactive, heteroduplex-based methods for identifying recurrent mutations in the BRCA1 and BRCA2 genes.
Mansukhani MM; Nastiuk KL; Hibshoosh H; Kularatne P; Russo D; Krolewski JJ
Diagn Mol Pathol; 1997 Aug; 6(4):229-37. PubMed ID: 9360844
[TBL] [Abstract][Full Text] [Related]
34. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
36. Founder BRCA 1 and 2 mutations among a consecutive series of Ashkenazi Jewish ovarian cancer patients.
Tobias DH; Eng C; McCurdy LD; Kalir T; Mandelli J; Dottino PR; Cohen CJ
Gynecol Oncol; 2000 Aug; 78(2):148-51. PubMed ID: 10926794
[TBL] [Abstract][Full Text] [Related]
37. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.
Lavie O; Hornreich G; Ben-Arie A; Rennert G; Cohen Y; Keidar R; Sagi S; Lahad EL; Auslander R; Beller U
Gynecol Oncol; 2004 Feb; 92(2):521-4. PubMed ID: 14766242
[TBL] [Abstract][Full Text] [Related]
38. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews.
Lalloo F; Cochrane S; Bulman B; Varley J; Elles R; Howell A; Evans DG
J Med Genet; 1998 Jan; 35(1):10-2. PubMed ID: 9475087
[TBL] [Abstract][Full Text] [Related]
39. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
[TBL] [Abstract][Full Text] [Related]
40. Analysis of several BRCA1 and BRCA2 mutations in a hospital-based series of unselected breast cancer cases.
Burcoş T; Cimponeriu D; Ion DA; Spandole S; Apostol P; Toma M; Radu I; Popa I; Stanilescu S; Popa E
Chirurgia (Bucur); 2013; 108(4):468-72. PubMed ID: 23958087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
